Accelerate Operating Income vs Interest Expense Analysis

AXDX Stock  USD 1.42  0.09  5.96%   
Accelerate Diagnostics financial indicator trend analysis is way more than just evaluating Accelerate Diagnostics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Accelerate Diagnostics is a good investment. Please check the relationship between Accelerate Diagnostics Operating Income and its Interest Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

Operating Income vs Interest Expense

Operating Income vs Interest Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Accelerate Diagnostics Operating Income account and Interest Expense. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Accelerate Diagnostics' Operating Income and Interest Expense is -0.66. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Accelerate Diagnostics, assuming nothing else is changed. The correlation between historical values of Accelerate Diagnostics' Operating Income and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Accelerate Diagnostics are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Operating Income i.e., Accelerate Diagnostics' Operating Income and Interest Expense go up and down completely randomly.

Correlation Coefficient

-0.66
Relationship DirectionNegative 
Relationship StrengthWeak

Operating Income

Operating Income is the amount of profit realized from Accelerate Diagnostics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Accelerate Diagnostics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.
Most indicators from Accelerate Diagnostics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Accelerate Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.At this time, Accelerate Diagnostics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 219.4 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 3.8 M in 2024.
 2023 2024 (projected)
Interest Income1.3M1.2M
Non Recurring2.7K2.4K

Accelerate Diagnostics fundamental ratios Correlations

0.780.040.430.70.08-0.210.140.760.540.020.980.250.140.52-0.140.320.510.251.0-0.58-0.57-0.1-0.680.04-0.32
0.780.26-0.060.810.52-0.670.440.380.76-0.260.660.710.540.70.370.720.730.690.75-0.55-0.520.34-0.50.16-0.73
0.040.26-0.270.370.25-0.540.60.040.37-0.04-0.030.430.280.020.290.530.290.30.02-0.26-0.250.230.350.11-0.47
0.43-0.06-0.27-0.24-0.820.55-0.180.47-0.410.590.55-0.51-0.25-0.5-0.59-0.37-0.55-0.40.47-0.12-0.12-0.25-0.23-0.590.66
0.70.810.37-0.240.59-0.660.380.460.94-0.290.60.650.350.810.280.650.880.580.66-0.61-0.60.1-0.480.45-0.77
0.080.520.25-0.820.59-0.660.14-0.30.7-0.7-0.060.690.280.810.50.520.840.50.03-0.13-0.140.23-0.260.64-0.83
-0.21-0.67-0.540.55-0.66-0.66-0.8-0.02-0.730.25-0.03-0.86-0.83-0.55-0.86-0.98-0.66-0.91-0.160.530.52-0.69-0.1-0.310.9
0.140.440.6-0.180.380.14-0.80.190.390.180.00.650.880.070.780.860.210.830.11-0.55-0.550.750.36-0.12-0.56
0.760.380.040.470.46-0.3-0.020.190.290.260.79-0.030.050.25-0.190.130.250.120.77-0.46-0.44-0.25-0.3-0.05-0.11
0.540.760.37-0.410.940.7-0.730.390.29-0.440.410.750.380.820.40.690.890.630.49-0.39-0.430.18-0.350.48-0.82
0.02-0.26-0.040.59-0.29-0.70.250.180.26-0.440.1-0.340.09-0.58-0.22-0.11-0.57-0.140.05-0.26-0.28-0.080.33-0.770.43
0.980.66-0.030.550.6-0.06-0.030.00.790.410.10.080.00.42-0.310.160.40.080.99-0.52-0.5-0.25-0.69-0.02-0.17
0.250.710.43-0.510.650.69-0.860.65-0.030.75-0.340.080.650.580.690.830.660.810.21-0.31-0.310.66-0.150.16-0.85
0.140.540.28-0.250.350.28-0.830.880.050.380.090.00.650.220.90.890.270.930.12-0.58-0.580.830.23-0.07-0.61
0.520.70.02-0.50.810.81-0.550.070.250.82-0.580.420.580.220.30.460.960.480.48-0.33-0.330.01-0.560.62-0.8
-0.140.370.29-0.590.280.5-0.860.78-0.190.4-0.22-0.310.690.90.30.830.340.89-0.17-0.35-0.350.840.330.21-0.68
0.320.720.53-0.370.650.52-0.980.860.130.69-0.110.160.830.890.460.830.570.920.29-0.62-0.620.730.070.18-0.83
0.510.730.29-0.550.880.84-0.660.210.250.89-0.570.40.660.270.960.340.570.530.47-0.38-0.380.05-0.450.63-0.89
0.250.690.3-0.40.580.5-0.910.830.120.63-0.140.080.810.930.480.890.920.530.22-0.55-0.550.760.050.12-0.79
1.00.750.020.470.660.03-0.160.110.770.490.050.990.210.120.48-0.170.290.470.22-0.57-0.56-0.12-0.680.01-0.28
-0.58-0.55-0.26-0.12-0.61-0.130.53-0.55-0.46-0.39-0.26-0.52-0.31-0.58-0.33-0.35-0.62-0.38-0.55-0.570.97-0.320.26-0.160.43
-0.57-0.52-0.25-0.12-0.6-0.140.52-0.55-0.44-0.43-0.28-0.5-0.31-0.58-0.33-0.35-0.62-0.38-0.55-0.560.97-0.30.22-0.140.42
-0.10.340.23-0.250.10.23-0.690.75-0.250.18-0.08-0.250.660.830.010.840.730.050.76-0.12-0.32-0.30.2-0.06-0.41
-0.68-0.50.35-0.23-0.48-0.26-0.10.36-0.3-0.350.33-0.69-0.150.23-0.560.330.07-0.450.05-0.680.260.220.2-0.270.12
0.040.160.11-0.590.450.64-0.31-0.12-0.050.48-0.77-0.020.16-0.070.620.210.180.630.120.01-0.16-0.14-0.06-0.27-0.44
-0.32-0.73-0.470.66-0.77-0.830.9-0.56-0.11-0.820.43-0.17-0.85-0.61-0.8-0.68-0.83-0.89-0.79-0.280.430.42-0.410.12-0.44
Click cells to compare fundamentals

Accelerate Diagnostics Account Relationship Matchups

Accelerate Diagnostics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets134.4M93.4M83.0M65.0M31.4M48.2M
Other Current Liab5.1M3.8M3.1M3.2M3.4M3.6M
Total Current Liabilities8.2M7.0M6.9M66.6M12.0M12.6M
Total Stockholder Equity(7.4M)(62.8M)(35.1M)(22.3M)(19.9M)(18.9M)
Property Plant And Equipment Net11.8M9.3M7.9M7.8M5.1M2.7M
Net Debt73.1M114.2M71.2M42.6M27.1M28.4M
Retained Earnings(414.7M)(493.0M)(570.7M)(607.2M)(668.9M)(635.4M)
Accounts Payable2.4M1.3M2.0M4.5M4.8M5.0M
Cash61.0M35.8M39.9M34.9M12.1M23.7M
Non Current Assets Total12.6M11.4M9.7M9.0M6.9M5.4M
Non Currrent Assets Other750K(5.9M)1.8M1.2M1.8M1.9M
Cash And Short Term Investments108.5M68.3M63.6M45.6M13.2M12.6M
Net Receivables3.2M1.6M2.3M2.4M2.6M2.8M
Common Stock Shares Outstanding5.4M5.5M5.6M6.2M12.5M13.1M
Liabilities And Stockholders Equity134.4M93.4M83.0M65.0M31.4M48.2M
Non Current Liabilities Total133.6M149.3M111.2M20.7M39.2M23.3M
Other Current Assets1.2M3.0M2.3M2.0M5.3M5.6M
Other Stockholder Equity407.3M430.0M535.6M585.3M649.6M682.0M
Total Liab141.8M156.2M118.1M87.3M51.3M28.6M
Property Plant And Equipment Gross11.8M9.3M7.9M7.8M16.1M16.9M
Total Current Assets121.9M82.0M73.3M56.0M24.5M42.8M
Accumulated Other Comprehensive Income(58K)91K(60K)(400K)(612K)(581.4K)
Common Stock Total Equity56K54K55K58K52.2K49.6K
Common Stock55K58K68K97K14K13.3K
Current Deferred Revenue271K376K451K547K1.5M1.6M
Other Liab19K335K808K1.5M1.4M1.5M
Other Assets750K5.3M1.8M1.2M1.00.95
Property Plant Equipment7.9M6.1M7.9M7.8M8.9M9.4M
Inventory8.1M9.2M5.1M5.2M3.3M2.7M
Net Tangible Assets(7.4M)(62.8M)(35.1M)(22.3M)(20.0M)(19.0M)
Long Term Debt130.0M145.9M108.0M16.9M36.1M51.1M
Retained Earnings Total Equity(330.3M)(414.7M)(493.0M)(570.7M)(513.6M)(487.9M)
Short Term Investments47.4M32.5M23.7M10.7M1.1M1.0M
Capital Surpluse432.9M452.3M475.1M580.7M667.7M701.1M
Non Current Liabilities Other3.6M3.4M3.2M874K1.2M1.6M
Short Long Term Debt Total134.1M150.0M111.1M77.5M39.2M37.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.